Année
2026
Auteurs
DE POUVOURVILLE Gérard, Guerci Bruno, Blanc‐Bisson Christèle, Vicaut Eric, Detournay Bruno, Emery Corinne, Bureau Isabelle, Ihaddadene‐Salzgeber Taos, Levrat‐Guillen Fleur, Riveline Jean‐Pierre
Abstract
The cost of treating patients with T2D is almost double that of controls without diabetes. However, the overall costs of treating diabetes in 2022 appear to be stable compared with 2013. Expanding access to new treatments and technologies could help improve clinical outcomes in T2D, potentially leading to reductions in costly complications. There is a need for improved health policies for people living with T2D in the overseas departments.
GUERCI, B., BLANC‐BISSON, C., VICAUT, E., DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. … RIVELINE, J. (2026). Economic burden of type 2 diabetes management in France according to clinical characteristics. Diabetes, Obesity and Metabolism, 28(5), pp. 4019-4032.